Literature DB >> 10847591

The nuclear corepressors recognize distinct nuclear receptor complexes.

R N Cohen1, A Putney, F E Wondisford, A N Hollenberg.   

Abstract

The thyroid hormone receptor (TR) and retinoic acid receptor (RAR) isoforms have the capacity to silence gene expression in the absence of their ligands on target response elements. This active repression is mediated by the ability of the corepressors, nuclear receptor corepressor (NCoR) and silencing mediator of retinoid and thyroid hormone receptors (SMRT), to recruit a complex containing histone deacetylase activity. Interestingly, NCoR and SMRT share significant differences in the their two nuclear receptor-interacting domains (IDs), suggesting that they may recruit receptors with different affinities. In addition, the role of the receptor complex bound to a response element has not been fully evaluated in its ability to recruit separate corepressors. We demonstrate in this report that the proximal ID in NCoR and SMRT, which share only 23% homology, allows preferential recognition of nuclear receptors, such that TR prefers to recruit NCoR, and RAR prefers to recruit SMRT, to DNA response elements. However, mutations in the TR found in the syndromes of resistance to thyroid hormone can change the corepressor recruited by changing the complex (homodimer or heterodimer) formed on the TRE. These results demonstrate that the corepressor complex recruited can be both nuclear receptor- and receptor complex-specific.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10847591     DOI: 10.1210/mend.14.6.0474

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  30 in total

1.  Determinants of CoRNR-dependent repression complex assembly on nuclear hormone receptors.

Authors:  X Hu; Y Li; M A Lazar
Journal:  Mol Cell Biol       Date:  2001-03       Impact factor: 4.272

2.  An unliganded thyroid hormone receptor causes severe neurological dysfunction.

Authors:  K Hashimoto; F H Curty; P P Borges; C E Lee; E D Abel; J K Elmquist; R N Cohen; F E Wondisford
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-06       Impact factor: 11.205

3.  SMRTε, a corepressor variant, interacts with a restricted subset of nuclear receptors, including the retinoic acid receptors α and β.

Authors:  Brenda J Mengeling; Michael L Goodson; William Bourguet; Martin L Privalsky
Journal:  Mol Cell Endocrinol       Date:  2012-01-12       Impact factor: 4.102

4.  Alternative mRNA splicing of SMRT creates functional diversity by generating corepressor isoforms with different affinities for different nuclear receptors.

Authors:  Michael L Goodson; Brian A Jonas; Martin L Privalsky
Journal:  J Biol Chem       Date:  2005-01-04       Impact factor: 5.157

5.  Heterodimers of retinoic acid receptors and thyroid hormone receptors display unique combinatorial regulatory properties.

Authors:  Sangho Lee; Martin L Privalsky
Journal:  Mol Endocrinol       Date:  2005-01-13

6.  Multiple mutations contribute to repression by the v-Erb A oncoprotein.

Authors:  Sangho Lee; Martin L Privalsky
Journal:  Oncogene       Date:  2005-10-13       Impact factor: 9.867

7.  Thyroid hormone receptor mutations found in renal clear cell carcinomas alter corepressor release and reveal helix 12 as key determinant of corepressor specificity.

Authors:  Meghan D Rosen; Martin L Privalsky
Journal:  Mol Endocrinol       Date:  2009-04-30

8.  Thyroid hormone signaling in vivo requires a balance between coactivators and corepressors.

Authors:  Kristen R Vella; Preeti Ramadoss; Ricardo H Costa-E-Sousa; Inna Astapova; Felix D Ye; Kaila A Holtz; Jamie C Harris; Anthony N Hollenberg
Journal:  Mol Cell Biol       Date:  2014-02-18       Impact factor: 4.272

9.  Structural basis for nuclear receptor corepressor recruitment by antagonist-liganded androgen receptor.

Authors:  Myles C Hodgson; Howard C Shen; Anthony N Hollenberg; Steven P Balk
Journal:  Mol Cancer Ther       Date:  2008-10       Impact factor: 6.261

10.  The nuclear corepressor, NCoR, regulates thyroid hormone action in vivo.

Authors:  Inna Astapova; Larissa J Lee; Crystal Morales; Stefanie Tauber; Martin Bilban; Anthony N Hollenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-03       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.